Key facts
- It has raised $1.5M; the latest was Accelerator/Incubator in Aug 2025.
- Notable investors include MedTech Innovator, Matter (Consulting Services (B2B)), Wellcome Trust, Cipher-Plexus Capital Advisors, IKP Knowledge Park — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Remidio
- ·The full record, as it builds
Funding rounds
No funding rounds for Remidio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Remidio
Developer of ophthalmic imaging devices designed to help diagnose eye diseases in both ophthalmic and nonophthalmic segments. The company's devices facilitate comprehensive eye testing and are integrated with offline, privacy-preserving artificial intelligence algorithms for the detection and monitoring of chronic and acute eye diseases, as well as systemic diseases, and are suitable for use in retail, home, and primary care centers, enabling surgeons to provide painless eye treatment and detect ophthalmic inconsistencies.
- Sector
- Healthcare
- HQ
- Bangalore, India
- Founded
- 2009
- Employees
- 120
- Website
- remidio.com/
- Ownership
- Privately Held (backing)
Remidio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Remidio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Remidio in its N-PORT filings yet. We sweep new filings monthly.